J.-P. Bronowicki

First interim analysis of the GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib) non-interventional study

Riccardo Lencioni, Masatoshi Kudo, S.-L. Ye et al. · International Journal of Clinical Practice · 2012 · 111 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Nomogram for individualized prediction of hepatocellular carcinoma occurrence in hepatitis C virus cirrhosis (ANRS CO12 CirVir)

Nathalie Ganne‐Carrié, Richard Layese, Valérie Bourcier et al. · Hepatology · 2016 · 94 citations · Full text

Medicine, Oncology, Hepatology +16

12 IL28B POLYMORPHISM PREDICTS VIROLOGIC RESPONSE IN PATIENTS WITH HEPATITIS C GENOTYPE 1 TREATED WITH BOCEPREVIR (BOC) COMBINATION THERAPY

F. Poordad, J.-P. Bronowicki, Stuart C. Gordon et al. · Journal of Hepatology · 2011 · 90 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +14

Multicentre randomised phase III trial comparing Tamoxifen alone or with Transarterial Lipiodol Chemoembolisation for unresectable hepatocellular carcinoma in cirrhotic patients (Fédération Francophone de Cancérologie Digestive 9402)

M Doffoël, Franck Bonnetain, O. Bouché et al. · European Journal of Cancer · 2008 · 87 citations

Medicine, Oncology, Pharmacology +14

Regional differences in sorafenib‐treated patients with hepatocellular carcinoma: <scp>GIDEON</scp> observational study

Masatoshi Kudo, Riccardo Lencioni, Jorge A. Marrero et al. · Liver International · 2016 · 50 citations · Full text

Medicine, Oncology, Cancer Epidemiology +16